Skip to search formSkip to main contentSkip to account menu

R 82913

Known as: Imidazo(4,5,1-jk)(1,4)benzodiazepine-2(1H)-thione, 9-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-, (S)-, R-82913, R82913 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Anti-HIV AgentsBenzodiazepinesImidazolesReverse Transcriptase Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of TIBO‐Like Cyclic Sulfones as Non‐Nucleoside HIV‐1 Reverse Transcriptase Inhibitors
TIBO‐ and TBO‐like sulfone derivatives 1 and 2 were designed, synthesized, and tested for their ability to block the replication… 
1995
1995
A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice.
1993
1993
Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
R82913 and R86183, two derivatives of tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione (TIBO), were found to potently… 
1993
1993
Rapid emergence of HIV-1 resistance to R82913 in only a minority of treated patients
1991
1991
TIBO R82913, a new HIV-1 inhibiting agent, does not inhibit hematopoietic progenitor cells.
In progressive stages of infection with human immunodeficiency virus type 1 (HIV-1), the majority of patients develop a… 
1991
1991
Pharmacokinetics of TIBO (R82913) in AIDS patients: a phase I study
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)